Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Turnstone Biologics Corp.

Turnstone Biologics develops new medicines to treat and cure patients with solid tumors. The company focuses on creating next-generation TIL therapies by selecting potent and tumor-reactive T cells for potential treatment across multiple solid tumors.

Turnstone Biologics

Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s next-generation TIL therapy is based upon the identification, selection and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in multiple Phase 1 studies in patients with colorectal cancer, breast cancer, head and neck cancer, uveal melanoma, and cutaneous melanoma. The Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com.

Takeda

FACIT

Versant Ventures

Eight Roads Ventures

F-Prime Capital

FACIT.com

OrbiMed

Sixty Degree Capital

Ridgeback Capital

Brace Pharma

JM Family Enterprises

Surveyor Capital

Teralys Capital

Northleaf Capital Partners

PFM Health Sciences

Point72

Yesterday, we announced our financial results and shared recent business highlights for Q2 2024, along with encouraging initial clinical data from the Phase 1 STARLING trial which supports the potential of our Selected TIL therapies in metastatic colorectal cancer and other high unmet need solid tumors. 
 
Read our full press release here ==> https://lnkd.in/gmyZJkzV
 
#TSBX #SelectedTIL #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #crc #colorectalcancer #solidtumors #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Turnstone reported today positive initial clinical data from the Phase 1 STARLING trial of TIDAL-01 in metastatic colorectal cancer. 
 
Key highlights from the initial data include the following:
 
–       Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC 
–       Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year 
–       Favorable tolerability profile and demonstrated manufacturing success
–       Product characterization and translational data support biological hypothesis for Selected TILs
 
The ORR and DCR observed with TIDAL-01 compare favorably to the standard of care for this patient population, where current therapies report a 1-6% ORR and median progression free survival (“mPFS”) of 2.0-5.6 months, and support the continued development of TIDAL-01 for patients with metastatic CRC and other solid tumors.

Read Turnstone’s press release to learn more about the encouraging initial data here -> https://lnkd.in/gbAXtbzU
 
#Clinicaldata #SelectedTIL #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #solidtumors #crc #colorectalcancer #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Congratulations to Dr. Maria Parkhurst and the talented team at the NCI Center for Cancer Research's Surgery Branch on their recent Nature Medicine* publication in which they demonstrated objective clinical responses in metastatic MSS colorectal cancer patients treated with #Tcells engineered from tumor-reactive TCRs identified from selected #TILs. 
 
#CRC remains the second leading cause of cancer deaths in the U.S. Particularly dire is the significant unmet medical need for patients with metastatic MSS CRC, for whom immunotherapies have sadly shown little to no clinical benefit. At Turnstone Biologics, we believe the key to overcoming challenges in historically difficult-to-treat “cold” tumors is increasing the number of on-target #tumor-reactive T cells, a #differentiated approach which forms the foundation for our Selected TIL therapy. This paper provides further evidence supporting the potential in metastatic MSS CRC when selecting and enriching for tumor-reactive T cells, and we are working tirelessly to improve outcomes for people afflicted with the disease through the clinical development of our next-generation Selected TIL program, TIDAL-01.  
 
Learn more about our novel TIDAL-01 process, designed to select a more potent population of T cells, here -> https://turnstonebio.com/.  
 
*The findings were published July 11, 2024, in Nature Medicine (Nature Portfolio) -> https://lnkd.in/ectSPuCX. 
 
#SelectedTIL #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #crc #colorectalcancer #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

It has officially been one year since Turnstone began trading as a public company, and what a year it has been.
 
As we look back on our achievements over the course of the past 12 months, we are extremely grateful for the relentless efforts and dedication of our incredible team, partners, collaborators, and all who have contributed to advancing our mission of expanding the frontiers of TIL therapy to solid tumor indications where we believe we can have the greatest impact on patients with our next-generation Selected TILs. 
 
We are proud to celebrate the one-year anniversary of our IPO and thank you to the wonderful team at Nasdaq for recognizing this milestone alongside everyone here at Turnstone. 
 
One year done, and we have only just begun. 
 
#TSBX #SelectedTIL #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #crc #colorectalcancer #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Today, we announced our financial results and shared recent business highlights for Q1 2024.

Read our full press release here ==> https://lnkd.in/gb5aRHes

#TSBX #Earnings #Nasdaq #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy #sandiego

May is #NationalCancerResearchMonth where we honor the important work being undertaken by researchers, advocates, clinicians, and healthcare professionals, and we are especially proud to recognize the unwavering spirit and relentless efforts of our team members and partners who devote their careers to advancing novel therapeutics in the fight against #cancer.
 
At Turnstone Biologics, we are resolutely committed to profoundly transforming the treatment paradigm for patients with harder-to-treat solid tumor indications where we believe we can have the greatest impact with next-generation TIL therapies that overcome the limitations of current treatment options.
 
Learn more about how we are working towards expanding the frontiers of TIL therapy with our differentiated “Selected TIL” technology at www.turnstonebio.com. 

#NCRM24 American Association for Cancer Research Moffitt Cancer Center Centre de recherche du CHUM (CRCHUM) #cancerresearch #researchanddevelopment #clinicalresearch #TSBX #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #lifesciences #clinicaltrials #CRC #colorectalcancer #headandneckcancer #uvealmelanoma #breastcancer #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

On Wednesday, May 15th, at 11:35 am PT (2:35 pm ET), our President and CEO, Dr. Sammy Farah, will present at the 2024 Bank of America Securities Health Care Conference. Tune in and learn more about why we believe we can expand the frontiers of TIL therapy into harder-to-treat solid tumor indications with critical unmet need, such as colorectal cancer, with Turnstone's next-generation “Selected TIL therapy”.

The webcast and replay details of the event can be accessed at Turnstone's Events page -> https://lnkd.in/gB7hRYKK.
 
Members of Turnstone’s senior management will also be available for 1x1 meetings during the conference, and we look forward to seeing you there. 
 
#TSBX #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #CRC #colorectalcancer #headandneckcancer #uvealmelanoma #breastcancer #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Tomorrow, our Chief Scientific Officer, Dr. Stewart Abbot, will present “Unveiling the Impact of Tumor-Infiltrating Lymphocytes (TILs) on Solid Tumors & the #TCR Landscape” at the 5th Annual TCR-Based Therapies for Solid Tumors Summit in #Boston. Amongst the topics to be covered are:
 
-Exploring the potential of "Selected TILs", Turnstone's next generation TIL therapy, as a groundbreaking avenue to combat solid tumors;
-Understanding the role of TILs as prognostic indicators and their ability to infiltrate solid tumor microenvironments;
-Delving into the diverse and specialized TCR repertoires present within Selected TILs.
 
Dr. Abbot will also be one of the expert guest speakers in a panel discussion evaluating effectiveness, indication suitability, and future modalities within the TCR therapy landscape. 
 
Learn more about the event here => https://lnkd.in/gF2zkg8

#Leadership #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #tcrtherapy #tcells #oncology #cancertreatment #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #team #opportunities #people #biotechnology #cellandgenetherapy Hanson Wade Group

We are delighted to welcome William D. Waddill to our Board of Directors.

Will brings to Turnstone Biologics more than 30 years of financial and operational expertise in the biotechnology space, and proven leadership in industry organizations, as we continue to advance clinical development of our lead Selected TIL therapy candidate, TIDAL-01.
 
Learn more here ==> https://lnkd.in/gEDcZtsq
 
#Leadership #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #cancertreatment #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #team #opportunities #people #biotechnology #cellandgenetherapy

Richly deserved.
 
Join us in congratulating Dr. Steven Rosenberg, Chief of the Surgery Branch at the National Cancer Institute in Bethesda, Maryland, for receiving the Award for Lifetime Achievement in Cancer Research from the American Association for Cancer Research, an award which honors an individual who has made significant fundamental contributions to cancer research. 

Amongst his countless accomplishments, Dr. Rosenberg led the first-ever clinical trials of TIL therapy, and his studies of cell transfer immunotherapy using tumor-infiltrating lymphocytes have resulted in durable complete remissions in patients with advanced solid cancers. 

We are grateful for Dr. Rosenberg’s vision and his tireless determination to meaningfully advance the field and to train generations of talented investigators, all of which enables the critical work we are undertaking with our Selected TIL programs.
  
#AACR24 #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

	Dec '21	Dec '22	Dec '23
account payables	28K -	3.44M 12,167.86%	36K 98.95%
accumulated other comprehensive income loss	-245K -	-413K 68.57%	-119K 71.19%
cash and cash equivalents	123.38M -	34.73M 71.85%	17.80M 48.75%
cash and short term investments	161.02M -	82.06M 49.04%	94.78M 15.50%
common stock	18K -	23K 27.78%	23K 0%
deferred revenue	33.03M -	15.14M 54.15%
deferred revenue non current	39.37M -	4.16M 89.43%
deferrred tax liabilities non current	171.75M -	171.94M 0.11%
goodwill
goodwill and intangible assets
intangible assets
inventory	382K -	382K 0%
long term debt	2.02M -	3.21M 58.35%	1.19M 62.90%
long term investments
net debt	-120.70M -	-29.57M 75.50%	-14.58M 50.67%
net receivables	6.71M -	8.73M 29.98%	194K 97.78%
other assets
other current assets	9.23M -	6.83M 25.98%	7.58M 11.02%
other current liabilities	21.26M -	14.29M 32.80%	9.91M 30.64%
other liabilities
other non current assets	536K -	2.58M 381.72%	1.14M 55.73%
other non current liabilities	172.72M -	174.21M 0.86%	989K 99.43%
othertotal stockholders equity	9.10M -	20.48M 125.07%	162.71M 694.42%
preferred stock			112.81M -
property plant equipment net	9.37M -	14.36M 53.28%	9.12M 36.48%
retained earnings	-90.72M -	-121.56M 33.99%	-176.76M 45.41%
short term debt	659K -	1.96M 197.57%	2.02M 3.26%
short term investments	37.64M -	47.33M 25.75%	76.98M 62.64%
tax assets
tax payables	252K -	252K 0%
total assets	187.24M -	114.94M 38.62%	112.81M 1.85%
total current assets	177.34M -	98.00M 44.74%	102.55M 4.65%
total current liabilities	54.98M -	34.83M 36.65%	11.97M 65.63%
total debt	2.68M -	5.17M 92.55%	3.21M 37.79%
total investments	37.64M -	47.33M 25.75%	76.98M 62.64%
total liabilities	269.10M -	216.41M 19.58%	14.15M 93.46%
total liabilities and stockholders equity	187.24M -	114.94M 38.62%	112.81M 1.85%
total non current assets	9.90M -	16.94M 71.06%	10.26M 39.42%
total non current liabilities	214.12M -	181.58M 15.20%	2.18M 98.80%
total stockholders equity	-81.85M -	-101.47M 23.97%	98.67M 197.24%

TSBX

COM:TURNSTONEBIO

Turnstone Biologics

Last Close

0.47

22/11 21:00

Market Cap

55.51M

Beta: -

Volume Today

151.33K

Avg: -

Preview